Chen Ying, Zhang Lei
Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China.
Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.
Exp Ther Med. 2017 Jul;14(1):10-17. doi: 10.3892/etm.2017.4488. Epub 2017 May 22.
MicroRNAs (miRs) are non-coding, single-stranded RNA molecules that regulate gene expression at the posttranscriptional level. Abnormal expression of miR may result in pathophysiological processes occurring that stimulate the development of various diseases. miRs are commonly dysregulated in cancer and may act as either oncogenes or tumor suppressors. Studies have indicated that members of the miR-200 family are involved in different aspects of cancer biology, including the epithelial-to-mesenchymal transition, tumor angiogenesis and chemoresistance by targeting and repressing the expression of several key messenger RNAs. The present review aims to summarize the role of the miR-200 family and its potential mechanism of action in tumor progression, which may advance the development of novel therapeutic drugs against tumor metastasis in clinical cancer treatment.
微小RNA（miRs）是一类非编码单链RNA分子，可在转录后水平调控基因表达。miR的异常表达可能引发病理生理过程，进而促进各种疾病的发展。miRs在癌症中通常表达失调，可能作为癌基因或肿瘤抑制因子发挥作用。研究表明，miR-200家族成员参与癌症生物学的不同方面，包括上皮-间质转化、肿瘤血管生成和化疗耐药性，其通过靶向并抑制几种关键信使RNA的表达来实现。本综述旨在总结miR-200家族在肿瘤进展中的作用及其潜在作用机制，这可能会推动临床癌症治疗中抗肿瘤转移新型治疗药物的研发。
